About US
Contact us
-
Gilead splashes out $21B for Immmunomedics, keeping the pedal on new target weeks after AZ-Daiichi dealIf industry watchers were amazed by AstraZeneca putting down up to $6 billion in July for a Daiichi Sankyo experimental TROP-2-directed cancer drug, they are now likely even more in awe of the size o2020/9/15
-
Eli Lilly, buoyed by Olumiant's COVID-19 data win, eyes emergency nod from FDAThe pharma industry’s massive pandemic response may have yielded another winner, as Eli Lilly’s Olumiant—combined with Gilead’sremdesivir—improved recovery timein patients hospitalized with COVID-19.2020/9/14
-
AbbVie to bring most employees back on site Monday despite COVID-19 concerns: reportAs newCOVID-19 new infections and deaths in the U.S. continue to march downward, companies are having to make a difficult choice: Stay at home or back to business as usual? For drugmaker AbbVie, this2020/9/14
-
Merck KGaA's MilliporeSigma pumps $65M into new facility for next-generation oncology medsMerck KGaA's MilliporeSigma unit morethan doubled itsgene therapy manufacturing capacity in April as it set its sights on the future. Now, the German drugmakeris making a big down payment on a new ma2020/9/11
-
AstraZeneca's COVID-19 vaccine production partner Emergent not likely to suffer if trial hold sticks: analystsAstraZeneca was humming right along with its partnered COVID-19 vaccine with the University of Oxford before a sudden trial hold threw its plans into disarray. So what does that uncertainty mean for2020/9/11
-
Novartis, Roche fined $526M in France for alleged Lucentis marketing misstepsSix years ago, the French Competition Authorityraidedthe local offices of Roche and Novartis in search of evidence of missteps in the way the companies were marketing Lucentis for age-related macular2020/9/10
-
Pfizer, BioNTech near Euro supply deal for up to 300M doses of COVID-19 vaccineIn the hunt for a COVID-19 vaccine, no front-runner is moving as quickly as Pfizer and BioNTech's mRNA-based shot, which is scoping an October regulatory review. Despite some technicalconcerns about2020/9/10
-
Catalent injects $130M into Maryland cell and gene therapy site drafted into COVID-19 vaccine huntNew Jersey contract manufacturer Catalent has been right in the mix in the COVID-19 response effort, signing pacts to help produce frontrunners in the vaccine hunt. Now, the company is fleshing out a2020/9/9
-
Takeda's selloff spree continues with $562M deal with Germany's CheplapharmWith last month’s $2.3 billion Japanese consumer health sale to Blackstone Group, Takeda has arguably achieved its $10 billion divestment goal. But the Japanese pharma is showing no sign of stopping2020/9/9
-
Mylan boosts Euro portfolio with $756M rights deal for Aspen's injectable thrombosis medsMylan's planned megamerger with Pfizer's Upjohn generics unit has had a rocky road to approval, with the novel coronavirus pandemic snagging regulatory review. Despite the delay, Mylan isn't twiddlin2020/9/8